CPHI [CHINA PHARMAS,] 424B3: (Original Filing)
[Form 10-K /A (Amendment No. 1 ) x For the fiscal year ended: December 31, 2008 o For the transition period from ______________ to _____________ China Pharma Holdings, Inc. Delaware 73-1564807]
CPHI [CHINA PHARMAS,] 424B3: Form 10-K /A (Amendment No. 1 ) x
[Form 10-K /A (Amendment No. 1 ) x For the fiscal year ended: December 31, 2008 o For the transition period from ______________ to _____________ China Pharma Holdings, Inc. Delaware 73-1564807]
CPHI [CHINA PHARMAS,] 424B3: (Original Filing)
[Form 10-K /A (Amendment No. 1 ) x For the fiscal year ended: December 31, 2008 o For the transition period from ______________ to _____________ China Pharmas, Delaware 73-1564807 (State or other jurisdiction (I.R.S. Employer I.D. No.)orporation or organization) 2nd Floor, No. 17, Jinpan Road, Haikou, Hainan Province, China 570216]
CPHI [CHINA PHARMAS,] 424B3: Form 10-K /A (Amendment No. 1 ) x
[Form 10-K /A (Amendment No. 1 ) x For the fiscal year ended: December 31, 2008 o For the transition period from ______________ to _____________ China Pharmas, Delaware 73-1564807 (State or other jurisdiction (I.R.S. Employer I.D. No.)orporation or organization) 2nd Floor, No. 17, Jinpan Road, Haikou, Hainan Province, China 570216]
CPHI [CHINA PHARMAS,] DEF 14C: (Original Filing)
[Payment of Filing Fee (Check the appropriate box): [X] No fee required. [ ] Fee computed on table below per Exchange Act Rules 14c-5(g) and 0-11. 1) Title of each class of securities to which transaction applies: 2) Aggregate number of securities to which transaction applies: 3)]
CPHI [CHINA PHARMAS,] DEF 14C: (Original Filing)
[Payment of Filing Fee (Check the appropriate box): [X] No fee required. [] Feemputed on table below per Exchange Act Rules 14c-5(g) and 0-11. 1) Title of each class of securities to which transaction applies: 2)gregate number of securities to which transaction applies: 3) 4) Proposed maximumgregate value of transaction:]
CPHI [CHINA PHARMAS,] DEF 14C: Payment of Filing Fee (Check the appropriate box):
[Payment of Filing Fee (Check the appropriate box): [X] No fee required. [] Feemputed on table below per Exchange Act Rules 14c-5(g) and 0-11. 1) Title of each class of securities to which transaction applies: 2)gregate number of securities to which transaction applies: 3) 4) Proposed maximumgregate value of transaction:]
CPHI [CHINA PHARMAS,] CORRESP: June 24, 2009 Attn: Mr. Jim B. Rosenberg
[June 24, 2009 Attn: Mr. Jim B. Rosenberg Re: China Pharma Holdings, Inc. Form 10-K for the Fiscal Year Ended December 31, 2008 Filed March 17, 2009 Form 10-KSB/A for the Fiscal Year Ended December 31, 2007 Forms 10-Q/A for the Quarterly Periods Ended March 31 and June 30, and September 30, 2008 Filed March 12, 2009 File No. 000-29523]
CPHI [CHINA PHARMAS,] 10-Q/A: (Original Filing)
[EXPLANATORY NOTE Except as set forth below, this Form 10-Q/A does not modify, amend or update in any way any other items or disclosure in the Form 10-Q. This Form 10-Q/A continues to speak as of the date of the original Form 10-Q and other than as specifically reflected in the Form 10-Q/A does not reflect events occurring after the] [Certification of Chief Executive Officer I, Zhilin Li, certify that: 2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by] [Financial Certification of Chief Officer I, Frank Waung, certify that: 2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER 18 U.S.C. SECTION 1350, Zhilin Li Chief Executive Officer EX-32.1 4 cph10qaex321033109.htm] [CERTIFICATION OF CHIEF FINANCIAL OFFICER 18 U.S.C. SECTION 1350, Frank Waung Chief Financial Officer EX-32.2 5 cph10qaex322033109.htm]
CPHI [CHINA PHARMAS,] 10-Q/A: EXPLANATORY NOTE Except as set forth below, this
[EXPLANATORY NOTE Except as set forth below, this Form 10-Q/A does not modify, amend or update in any way any other items or disclosure in the Form 10-Q. This Form 10-Q/A continues to speak as of the date of the original Form 10-Q and other than as specifically reflected in the Form 10-Q/A does not reflect events occurring after the] [Certification of Chief Executive Officer I, Zhilin Li, certify that: 2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by] [Financial Certification of Chief Officer I, Frank Waung, certify that: 2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER 18 U.S.C. SECTION 1350, Zhilin Li Chief Executive Officer EX-32.1 4 cph10qaex321033109.htm] [CERTIFICATION OF CHIEF FINANCIAL OFFICER 18 U.S.C. SECTION 1350, Frank Waung Chief Financial Officer EX-32.2 5 cph10qaex322033109.htm]
